CIBER de Enfermedades Respiratorias (CIBERES), Spain; Department of Pneumology, Hospital Clínic of Barcelona, August Pi i Sunyer Biomedical Research Institute-IDIBAPS, University of Barcelona, Barcelona, Spain.
CIBER de Enfermedades Respiratorias (CIBERES), Spain; Department of Pneumology, Hospital Clínic of Barcelona, August Pi i Sunyer Biomedical Research Institute-IDIBAPS, University of Barcelona, Barcelona, Spain.
Arch Bronconeumol. 2022 Apr;58 Suppl 1:22-31. doi: 10.1016/j.arbres.2022.03.010. Epub 2022 Apr 15.
The COVID-19 pandemic created tremendous challenges for health-care systems. Intensive care units (ICU) were hit with a large volume of patients requiring ICU admission, mechanical ventilation, and other organ support with very high mortality. The Centro de Investigación Biomédica en Red-Enfermedades Respiratorias (CIBERES), a network of Spanish researchers to investigate in respiratory disease, commissioned the current proposal in response to the Instituto de Salud Carlos III (ISCIII) call.
CIBERESUCICOVID is a multicenter, observational, prospective/retrospective cohort study of patients with COVID-19 admitted to Spanish ICUs. Several work packages were created, including study population and ICU data collection, follow-up, biomarkers and miRNAs, data management and quality.
This study included 6102 consecutive patients admitted to 55 ICUs homogeneously distributed throughout Spain and the collection of blood samples from more than 1000 patients. We enrolled a large population of COVID-19 ICU-admitted patients including baseline characteristics, ICU and MV data, treatments complications, and outcomes. The in-hospital mortality was 31%, and 76% of patients required invasive mechanical ventilation. A 3-6 month and 1 year follow-up was performed. Few deaths after 1 year discharge were registered. Low anti-SARS-CoV-2 S antibody levels predict mortality in critical COVID-19. These antibodies contribute to prevent systemic dissemination of SARS-CoV-2. The severity of COVID-19 impacts the circulating miRNA profile. Plasma miRNA profiling emerges as a useful tool for risk-based patient stratification in critically ill COVID-19 patients.
We present the methodology used in a large multicenter study sponsored by ISCIII to determine the short- and long-term outcomes in patients with COVID-19 admitted to more than 50 Spanish ICUs.
COVID-19 大流行给医疗保健系统带来了巨大挑战。重症监护病房(ICU)收治了大量需要 ICU 入院、机械通气和其他器官支持的患者,死亡率非常高。西班牙研究呼吸疾病的研究网络 Centro de Investigación Biomédica en Red-Enfermedades Respiratorias(CIBERES),响应 Instituto de Salud Carlos III(ISCIII)的号召,委托开展了当前的研究。
CIBERESUCICOVID 是一项多中心、观察性、前瞻性/回顾性队列研究,纳入了入住西班牙 ICU 的 COVID-19 患者。创建了多个工作包,包括研究人群和 ICU 数据收集、随访、生物标志物和 miRNA、数据管理和质量。
该研究纳入了 6102 例连续入住 55 家 ICU 的患者,这些 ICU 均匀分布在西班牙各地,并从 1000 多名患者中采集了血液样本。我们纳入了大量 COVID-19 ICU 入院患者,包括基线特征、ICU 和 MV 数据、治疗并发症和结局。住院死亡率为 31%,76%的患者需要有创机械通气。进行了 3-6 个月和 1 年的随访。出院 1 年后仅记录到少数死亡病例。COVID-19 重症患者的 SARS-CoV-2 中和抗体 S 水平较低预示着死亡率升高。这些抗体有助于防止 SARS-CoV-2 的全身传播。COVID-19 的严重程度影响循环 miRNA 谱。血浆 miRNA 谱分析成为对危重症 COVID-19 患者进行基于风险的患者分层的有用工具。
我们介绍了由 ISCIII 资助的一项大型多中心研究中使用的方法学,以确定入住西班牙 50 多家 ICU 的 COVID-19 患者的短期和长期结局。